Hanmi Pharm in spotlight as Korea's 1st obesity drug nears launch
Hanmi Pharmaceutical is gaining attention as it prepares to launch Korea’s first glucagon-like peptide-1 (GLP-1)-based obesity drug, Eppe, while also signing a licensing deal worth up to $2.3 billion for a separate obesity drug candidate. In recent weeks, a series of analysts at domestic brokerages have raised their price target on Hanmi Pharm, citing the company’s potential in obesity drugs. “We…
Hanmi Pharmaceutical is currently in the spotlight as its first obesity drug, Eppe, a glucagon-like peptide-1 (GLP-1)-based medication, approaches launch in Korea. The company is also engaged in a licensing agreement valued at up to $2.3 billion for another obesity drug candidate. Recent analyst activity from domestic brokerages has been focusing on Hanmi Pharm's potential in the obesity drug market.
Analysts at DS Securities have raised their price target for Hanmi Pharm to 720,000 won, citing the expected domestic approval and launch of Eppe, along with the release of Phase 1 trial results for HM17321. Similarly, Samsung Securities has increased its price target on Hanmi Pharm to 610,000 won, up from 500,000 won, also highlighting the potential of HM17321.
Both Eppe and HM17321 are crucial drugs in Hanmi Pharm's pipeline for obesity treatments. Eppe is a long-acting GLP-1 obesity treatment developed using Hanmi Pharm's proprietary platform technology called Lapscovery.
Written by urgent.news from The Korea Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
Also reported by 1 other outlet
- Hanmi Pharm in spotlight as Korea's 1st obesity drug nears launch koreatimes.co.kr
